ClinicalTrials.gg
CompletedNCT07008547Updated Sep 10, 2026

To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of Netakimab and Placebo in Plaque Psoriasis, sponsored by SPH-BIOCAD (HK) Limited. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by SPH-BIOCAD (HK) Limited · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2024, registered May 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
82nd of 182
202 · median 171
Started
2024
with 24 others
Phase 3
58 of 206
16 open now
Registered
159th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 82nd largest by enrollment of the 182 interventional ones that give a count, is one of 25 that started in 2024, is one of 58 in phase 3, and was the 159th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with moderate to severe plaque psoriasis. Researchers will compare Netakimab to placebo to see if Netakimab works to treat plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must voluntarily sign and date an Form (ICF) approved by the Ethics Committee (IEC) prior to any study-related procedures. The legal representative may also be asked to sign the ICF in accordance with local laws and regulations if necessary.
  • Male or female, ≥ 18 years old at the time of signing the ICF.
  • Patients with plaque psoriasis diagnosed at least for 6 months prior to signing the ICF.
  • Patients who have inadequate response or intolerance to phototherapy or systemic drug therapy (biological or non-biological agents other than IL-17/IL-17R inhibitors) for psoriasis, or meet the above treatment indications in the opinion of the investigator.
  • Patients with psoriasis involved body surface area (BSA) of 10% or more, PASI score of 10 or more, and sPGA score of 3 or more at screening.
  • have a negative serum pregnancy test (no pregnancy test is required for women of non-childbearing potential).
  • Patients of childbearing potential and their partners must implement reliable measures as specified in the protocol from signing the ICF until 20 weeks after the last dose of study treatment (see Appendix 10 for details).
  • Patients who have the ability to follow protocol procedures as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Patients with other types of psoriasis (e.g., erythrodermic psoriasis, pustular psoriasis, guttate psoriasis) or any other skin disorders (e.g., eczema) that may affect the treatment/evaluation of psoriasis, and patients with drug-induced psoriasis or a history of drug-induced psoriasis at screening.
  • Patients who are unable or unwilling to undergo repeated subcutaneous injection and venipuncture (e.g., because of poor tolerability or lack of venous access).
  • Patients who have received the prohibited drugs or vaccines as specified in the protocol:
  • Patients with virus (HBV) infection, virus (HCV) infection, (HIV) infection, treponema pallidum (TP) infection.
  • Patients meeting any of the following criteria for laboratory tests at screening: serum creatinine (Cr) > 1.5 × (ULN); (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) > 2.5 × ULN; total (TBIL) > 1.5 × ULN; white blood cell (WBC) count \< 3.0 × 109/L; (ANC) \< 2.0 × 109/L; (PLT) count \< 100 × 109/L; (Hb) \< 90 g/L.
  • Patients with any psychiatric disorders, including serious depressive disorder, or history of strong suicidal ideation or suicide intention; or symptoms of depression (Beck score ≥ 16 at screening), which require intervention treatment determined by a specialist.
  • Patients with history or evidence of alcohol or drug abuse.
  • Patients with active tuberculosis infection or history of tuberculosis, or current latent tuberculosis infection [positive for interferon gamma release assay (QuantiFERON TB-Gold or T-SPOT etc.)].
  • Patients with other diseases that may affect the assessment of psoriasis or any other underlying disease (including, but not limited to, clinically significant cardiac, hepatic, renal, respiratory, immune, neurological, endocrine, metabolic, blood, gastrointestinal, or psychiatric disorders) that, in the opinion of the investigator, study treatment may place the patient at additional risks
  • Patients with current or previous malignant tumor within the past 5 years [except adequately treated (cured) squamous cell carcinoma or basalioma, cervical uteri cancer in situ or in situ breast ductal carcinoma].
  • Patients with known history of serious allergies (allergies to two or more drugs or systemic allergic reactions).
  • Patients with known allergies or intolerance to monoclonal antibody drugs or any other component of the product or placebo.
  • Patients who have had major surgery within 30 days prior to screening or scheduled for major surgeries at any time during the study.
  • Patients with active infection or medical history:
  • Patients with epileptic seizure or the history of epileptic seizure.
  • Patients who are pregnant, breastfeeding, or planning pregnancy at the time of study participation.
  • Patients who have participated in any other clinical study or within 3 months prior to signing the ICF or are concurrently participating in other clinical studies.
  • Patients who have other conditions that are not suitable for participation in the study in the judgment of the investigat
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Netakimab

    Netakimab administered by subcutaneous injection until Week 52

    Biological: Netakimab

  • Placebo comparator
    Placebo

    Placebo administered by subcutaneous injection until Week 12 then Netakimab subcutaneous injection until 52 week

    Biological: Netakimab · Drug: Placebo

Interventions

  • BiologicalNetakimab

    Netakimab administered subcutaneously

  • DrugPlacebo

    Placebo administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving PASI75

    Proportion of subjects with a Psoriatic Area and Severity Index (PASI) score improved by at least 75% (to achieve a PASI 75 response) relative to the baseline PASI score at Week 12

    Time frame: at week 12

  2. Proportion of subjects achieving sPGA0/1

    Proportion of subjects with a sPGA(Static Physician Global Assessment) either 0 or 1 at Week 12

    Time frame: at week 12

Secondary outcomes

  1. Proportion of subjects achieving PASI75

    Proportion of subjects with a Psoriatic Area and Severity Index (PASI) score improved by at least 75% (to achieve a PASI 75 response) relative to the baseline PASI score through out the study

    Time frame: through out the study(From baseline to Week 62)

  2. Proportion of subjects achieving PASI90

    Proportion of subjects with a Psoriatic Area and Severity Index (PASI) score improved by at least 90% (to achieve a PASI90 response) relative to the baseline PASI score through out the study

    Time frame: through out the study(From baseline to Week 62)

  3. Proportion of subjects achieving PASI100

    Proportion of subjects with a Psoriatic Area and Severity Index (PASI) score improved by at least100% (to achieve a PASI100 response) relative to the baseline PASI score through out the study

    Time frame: through out the study(From baseline to Week 62)

  4. Proportion of subjects achieving PGA

    Proportion of subjects with a sPGA(Static Physician Global Assessment) either 0 or 1 through out the study

    Time frame: through out the study(From baseline to Week 62)

  5. Changes from baseline in NAPSI score

    Changes from baseline in NAPSI score through out the study

    Time frame: through out the study(From baseline to Week 52)

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Mar 2025, 7 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 6, 2025
StartActual
Jul 30, 2024
Primary completionActual
Mar 28, 2025
CompletionActual
Mar 9, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07008547
Lead sponsor
SPH-BIOCAD (HK) Limited
Responsible party
Sponsor
First posted
Jun 6, 2025
Start date
Jul 30, 2024
Primary completion
Mar 28, 2025
Completion
Mar 9, 2026
Last update
Sep 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netakimab

Start the discussion